Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Bristol-Myers Squibb should soon unveil data showing whether Opdivo’s liver cancer use could be broadened from second to first line, while Amicus investors look for a…
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
Roche will find out by September 5 whether its shot at a first-line US lung cancer label has hit the mark.